If you’ve followed the news around medications like Ozempic, Wegovy, or Mounjaro, you’ve probably heard about their effects on weight and blood sugar. What’s gotten far less attention — but is generating real excitement among addiction researchers — is a pattern showing up again and again in clinics, research studies, and patient reports: people taking these medications for diabetes or weight loss are describing a sharp drop in cravings for alcohol, nicotine, and other substances, sometimes without even trying to quit.
This isn’t a treatment we offer, and it isn’t an approved use of these medications. But the research is moving quickly enough that it’s worth understanding, especially if you or someone you love is navigating recovery. Here’s where the science actually stands.
What are GLP-1 medications?
GLP-1 receptor agonists — medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — were developed to treat type 2 diabetes and obesity. They work by mimicking a natural gut hormone that regulates insulin, slows digestion, and promotes feelings of fullness. That’s the effect they were designed for, and it’s the reason millions of people are now taking them.
What researchers didn’t initially expect is that this same hormone system reaches far beyond the gut. GLP-1 receptors exist throughout the brain, including in regions tied to reward, motivation, and habit — the same circuitry involved in addiction.
What the research shows so far
The strongest evidence to date is in alcohol use disorder. In 2026, The Lancet published the largest randomized, placebo-controlled trial of its kind — 108 adults with both alcohol use disorder and obesity, given either weekly semaglutide or a placebo alongside standard therapy for 26 weeks. Heavy drinking days dropped significantly more in the semaglutide group than the placebo group. An earlier trial published in JAMA Psychiatry found similar results, with semaglutide reducing drinking frequency and craving intensity in adults with alcohol use disorder.
The signal isn’t limited to alcohol. Large observational studies — including a cohort analysis of more than 600,000 U.S. veterans with type 2 diabetes — have found that patients started on a GLP-1 medication had lower rates of new diagnoses across several substance use disorders compared to those started on a different diabetes medication. Other research has linked GLP-1 use to fewer nicotine-related health visits and reduced opioid overdose risk in patients already receiving medication-assisted treatment. A pilot study is currently underway to test whether semaglutide can help with methamphetamine use disorder as well.
Why might a diabetes drug affect cravings?
The leading theory involves the brain’s reward pathway — the same system that assigns importance and pull to things like food, alcohol, or drugs. GLP-1 signaling reaches the ventral tegmental area and nucleus accumbens, two regions central to dopamine release and reward, as well as the prefrontal cortex, which governs impulse control. Researchers believe these medications may dampen the reward response to substances and strengthen the brain’s ability to resist automatic urges — which could explain why patients describe cravings simply losing their pull, without consciously trying to quit.
An important caution
It’s easy to get ahead of the evidence here, so we want to be direct: no GLP-1 medication is currently FDA-approved to treat any substance use disorder. Every use for addiction today is off-label. The strongest data is in alcohol use disorder, and even there, the largest trial studied a specific population — adults who also had obesity. Evidence for opioid, nicotine, and stimulant use disorders is earlier still, based mostly on animal studies, patient reports, and observational data rather than large randomized trials.
That doesn’t mean the research isn’t promising — it’s some of the most closely watched work in addiction medicine right now. But it means these medications aren’t a substitute for established, evidence-based treatment today.
What this means for your recovery
If you’re already taking a GLP-1 medication for diabetes or weight management and you’re also working on recovery, it’s worth mentioning to your care team — not because it changes your treatment plan, but because your full picture matters. If you’re curious whether a GLP-1 medication could someday play a role in addiction treatment, that’s a conversation to have with a physician, not a reason to delay care that we know works today, like medication-assisted treatment paired with counseling.
Research like this is part of why the field of addiction medicine keeps evolving — and it’s exactly why we stay current on it. But the most effective path forward for opioid or alcohol use disorder today remains what we practice every day at Miami Valley Recovery: proven medications, real counseling, and a plan built around you.